Doc. Says Martoma Knew Test Results In Advance

Jan 16 2014 | 12:47pm ET

A prominent doctor testified yesterday that former SAC Capital Advisors portfolio manager Mathew Martoma appeared to know the results of a disappointing drug test before he did.

Joel Ross, who has admitted passing secret information about the same drug trials to Martoma, told the jury he was "flabbergasted" when he ran into Martoma following a confidential presentation on an Alzheimer's drug in July 2008.

"It was like he was in the room with me, with the slides I had just seen," Ross said. Prosecutors allege that Martoma had already received the results, which were not to be made public until the day after the conference, from another doctor working on the trial, Sidney Gilman. Gilman is set to testify later in the trial.

In the lobby of a Chicago hotel after the "somber" meeting—where Elan Corp. executive Michael Grundman announced "the drug did not work at all," Ross said—Martoma spoke of precise statistical measures from the study.

When Ross told Martoma he was still optimistic, Martoma allegedly replied, "I don't understand how you can say that with the statistical evidence showing otherwise."

"I think he knew the exact numbers," Ross said, adding that it was the last time he saw Martoma.

Ross also spoke of his first contact with the Federal Bureau of Investigation, admitting that he lied when he got a phone call from an agent in 2012. And he faced some tough questions from Martoma's lawyer, Roberto Braceras, who sought to show that the information about the drug was publicly available.

Braceras also questioned Ross about the affect of Martoma's indictment on his drug-trial business. Ross said he had lost significant business.

"Do you think this is about money?" Braceras shot back. "My client's life is at stake here and you're complaining about losing money?"

U.S. District Judge Paul Gardephe sustained an objection to the question.


In Depth

bfinance: Fees Falling Across Asset Classes, Yet Overall Investor Costs Still Climbing

May 16 2017 | 9:53pm ET

Despite unprecedented attention on fees, new research from investment consultancy...

Lifestyle

Aston Martin Returns To Debt Market As DB11 Drives Turnaround

Mar 31 2017 | 5:21pm ET

James Bond’s preferred carmaker is returning to the public debt markets for the...

Guest Contributor

Risk-Based Compliance: Why Oversight Of Outsourcing Is Critical

May 10 2017 | 7:02pm ET

Compliance is notoriously one of the trickiest middle office functions for funds...

 

From the current issue of